Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 14, 2009

View Archived Issues

First pediatric patient treated with Aptocine in neurofibromatosis study

Hana reaches enrollment target for phase II Marqibo trial in ALL

Zilver PTX Drug-Eluting Peripheral Stent receives approval in Europe

Antisoma and Bryan Oncor enter agreement for anticancer drug P-2045

Neurobiological Technologies terminates agreement with Merz and CMCC

Dynavax meets with EMEA for Heplisav HBV vaccine development strategy

FDA accepts to file Theratechnologies' tesamorelin NDA

Kuros reports data with KUR-212 in burn victims requiring mesh grafting

Labopharm submits response to FDA complete response letter for trazodone

Vedrop receives marketing authorization in the European Union

Tolerx amends phase III DEFEND protocol

Anadys reports viral load data for ANA-773 in hepatitis C patients

Avanir presents phase III study results for Zenvia

Anti-bovine thrombin 4A IgG cross-reacts with human thrombin and Recothrom

CB1/CB2 receptor antagonist THCV displays anticonvulsant activity in rat model of epilepsy

Novel antithrombotic agent S-35972 displays promising preclinical activity

Preclinical and early clinical data indicate that EP-42675 is a potent anticoagulant

O-3223 shows potency in preclinical models of inflammatory and neuropathic pain

PF-2341066 displays clinical activity in EML4-ALK translocation-positive NSCLC

Wyeth identifies liver X receptor modulators for the treatment of lipoprotein disorders

MEK kinase inhibitors for cancer treatment presented by Genentech

LG Life Sciences claims glucokinase activators for the treatment of diabetes

Merck & Co. describe c-Met kinase inhibitors for cancer treatment

Novel alpha2-adrenoceptor ligands in early development at Allergan

Novel tyrosine hydroxylase inducers discovered by French investigators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...